Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
MindMed Q3 2025 Earnings Call - Strong Phase 3 Enrollment and $259M Financing Set Stage for 2026 Catalysts
MindMed celebrated a robust Q3 2025, spotlighting the publication of its Phase 2B trial results for MM120 ODT in JAMA, underscoring clinical rigor and promising efficacy in generalized anxiety disorde...
- Published full Phase 2B results for MM120 ODT in JAMA demonstrating significant anxiety reduction and remission rates at 12 weeks post-single dose.
- Raised approximately $259 million gross in an underwritten public offering, enhancing financial position and enabling acceleration of MM120 and MM402 development.
- Cash and investments total $209.1 million at quarter-end; net proceeds expected to fund operations into 2028.
- +13 more takeaways
SanDisk Fiscal Q1 2026 Earnings Call - Strong Demand Drives Growth Amid Supply Constraints and Strategic Customer Engagements
SanDisk reported a robust start to fiscal year 2026 with revenue rising 21% sequentially to $2.3 billion and non-GAAP EPS soaring to $1.22, propelled by strengthening demand across data center, edge, ...
- SanDisk's fiscal Q1 2026 revenue was $2.3B, up 21% sequentially, with non-GAAP EPS of $1.22, beating guidance.
- Data center revenue grew 26% sequentially, driven by hyperscaler and OEM customer demand and strategic qualifications of new products.
- Demand for NAND products continues to outpace supply, a dynamic expected to last through 2026 and beyond, forcing allocation of supply to strategic customers.
- +13 more takeaways
Yelp Q3 2025 Earnings Call - AI-Driven Services Growth Offsets RRNO Pressures in Challenging Macro Environment
Yelp reported a record Q3 2025 performance with net revenue hitting $376 million, propelled by a 7% increase in services revenue despite a 2% decline in Restaurants, Retail, and Non-Restaurant Other (...
- Yelp’s Q3 2025 net revenue reached a record $376 million, up 4% year over year.
- Services revenue grew by 7%, hitting a quarterly record of $244 million, while RRNO revenue declined 2%.
- AI-driven initiatives rolled out over 35 new features, significantly enhancing the consumer and business experience.
- +10 more takeaways
Karat Packaging Q3 2025 Earnings Call - Robust Sales Growth Amid Margin Pressures and Strategic Shift to Domestic Sourcing
Karat Packaging delivered another quarter of strong top-line growth, with net sales up 10.4% year-over-year to $124.5 million, driven by volume expansion, a favorable product mix, and effective pricin...
- Karat Packaging reported Q3 2025 net sales of $124.5 million, a 10.4% increase year-over-year, driven by volume growth and favorable product mix.
- The company maintained a gross margin of 34.5%, down from 38.6% year-over-year due to higher import duties and tariffs increasing import costs to 14.4% of net sales.
- Domestic sourcing increased to 20% in Q3 from 15% in Q2, while imports from Taiwan fell from 58% to 42%, reflecting a strategic move to diversify supply and reduce tariff exposure.
- +12 more takeaways
Ambiq Micro Q3 2025 Earnings Call - Strong AI-Driven Growth and Apollo 5 Momentum Outpace Market Expectations
Ambiq Micro's Q3 2025 earnings reveal a strategic pivot paying dividends with sales beating expectations and gross margins hitting new highs. The company’s laser focus on edge AI, led by the Apollo 5 ...
- Ambiq Micro exceeded Q3 2025 net sales expectations with $18.2 million, despite a 10.4% year-over-year decline due to strategic exit from low-margin China customers.
- Achieved non-GAAP gross margin of 44.8%, up over 10 percentage points YoY, reflecting a favorable product mix focused on high-value edge AI solutions.
- Apollo 5 platform is a core driver of growth, with strong adoption in Q4 and expected to fuel revenue acceleration into 2026 and beyond.
- +12 more takeaways
Crinetics Pharmaceuticals Q3 2025 Earnings Call - Promising Launch of Palsanafy Sets Stage for Growth
Crinetics Pharmaceuticals marked a pivotal year with the commercial launch of Palsanafy, a novel oral therapy for acromegaly, showing encouraging early adoption across community and pituitary treatmen...
- Palsanafy oral therapy for acromegaly has launched nationally with initial patient shipments occurring 11 days post-approval and robust early uptake.
- The launch strategy prioritizes switching patients from injectable SRLs, activating treatment-naive patients, and later reengaging patients lost to follow-up.
- Early prescribing is well-balanced with 70% from community endocrinologists and 30% from specialized pituitary centers.
- +7 more takeaways
Progyny Q3 2025 Earnings Call - Strong Selling Season and Raised Guidance Amid Market Headwinds
Progyny delivered a robust Q3 2025 with revenue and profitability surpassing guidance expectations, driven by sustained member engagement and an energized selling season despite macroeconomic and medi...
- Progyny raised its full year 2025 revenue guidance for the third consecutive quarter, now up by over $70 million from original estimates.
- Q3 revenue growth was 9% on an as-reported basis and 23% excluding a large former client under a transition agreement.
- Approximately 900,000 new covered lives were added in the current selling season, slightly below the 1 million target but above expectations.
- +13 more takeaways
Natera 2025 Third Quarter Earnings Call - Record Signatera Growth, Strong Financial Outlook, and Expansion into Early Cancer Detection
Natera delivered a robust Q3 2025, with revenue up 35% year-over-year to $592 million and record clinical MRD test volumes exceeding 202,000 units, driven by significant growth in Signatera. The compa...
- Natera reported Q3 2025 revenue of $592 million, up 35% year-over-year, with strong volume growth across its clinical product portfolio.
- Signatera MRD tests hit a new high at 202,000 units processed, growing 56% year-over-year, driven by broad tumor type adoption and new patient starts.
- Gross margins improved significantly to 64.9% in Q3, nearly 1.5 percentage points higher than Q2, supported by ASP improvements and operational efficiencies.
- +7 more takeaways
Motorsport Games Q3 2025 Earnings Call - Profitability Achieved on Back of Le Mans Ultimate Growth and Console Expansion Plans
Motorsport Games reported a profitable third quarter in 2025, driven by strong sales growth in its flagship product Le Mans Ultimate and its online subscription platform Race Control. Having exited St...
- Motorsport Games achieved operational profitability for the second consecutive quarter in Q3 2025.
- Total revenue in Q3 2025 rose 71.9% year-over-year to $3.1 million, primarily from Le Mans Ultimate and Race Control.
- Le Mans Ultimate exited Steam Early Access with record-high concurrent and daily active users, independent of real-world event timing.
- +9 more takeaways
Arlo Technologies Q3 2025 Earnings Call - Powered by Record SaaS Growth and Product Launch
Arlo Technologies delivered a record-breaking Q3 2025, driven by an exceptional surge in its SaaS business and the largest product launch in company history. The company added 281,000 paid accounts, s...
- Arlo added 281,000 paid subscriber accounts in Q3, surpassing its guidance range of 190,000-230,000, pushing total paid accounts to 5.4 million.
- Annual recurring revenue (ARR) rose 34% year-over-year to $323 million, marking a new company record.
- Service gross margins expanded by 770 basis points to over 85%, driven by increased ARPU and reduced cost to serve.
- +12 more takeaways